Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia (Q36988579)

17 August 2017

1 reference

title

Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia (English)

1 reference

17 August 2017

1 reference

1 reference

Jane F Apperley

1

1 reference

17 August 2017

1 November 2007

1 reference

Lancet Oncology Commission

17 August 2017

1 reference

17 August 2017

8

1 reference

17 August 2017

11

1 reference

17 August 2017

1018-1029

1 reference

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

17 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Genotype???phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Expression of the multidrug transporter, P-glycoprotein, in chronic myelogenous leukaemia cells in blast crisis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Active transport of imatinib into and out of cells: implications for drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

hOCT 1 and resistance to imatinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to Imatinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

An amino-acid switch in the BCR-ABL kinase domain modifies sensitivity to imatinib mesylate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Drug resistance in cancer: principles of emergence and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec/Glivec).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970342-X

7 January 2021

10.1016/S1470-2045(07)70342-X

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

17976612